Recordati‘s inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for the treatment of people with endogenous Cushing’s syndrome, the company announced. The decision follows a European Medicines Agency (EMA) committee recommendation in November to approve Isturisa for that…
News
One year of treatment with under-the-skin Signifor (pasireotide) lessens tumor volume in many Cushing’s disease patients for whom surgery has failed or is not an option, a post-hoc analysis of a Phase 3 clinical trial shows. Signifor was found to normalize urinary cortisol levels and ease…
People diagnosed with Cushing’s disease during childhood may experience lowered pituitary hormones long after receiving surgery, as well as mood and cognitive disorders, a long-term follow-up study shows. The study, “Long-Term Outcome in Patients After Treatment for Cushing’s Disease in Childhood,” was published in the journal PLoS…
A diagnostic technique called bilateral inferior petrosal sinus sampling (BIPSS), which measures the levels of the adrenocorticotropic hormone (ACTH) produced by the pituitary gland, should only be used to diagnose cyclic Cushing’s syndrome patients during periods of cortisol excess, a case report shows. When it…
People with Cushing’s syndrome often experience a rise in blood pressure that puts them at a significant risk of cardiovascular ills, but most improve within 10 days after surgery to treat their hypercortisolism, a study found. Nonetheless, fewer than half see their blood pressure normalized within one year of surgical…
Cushing’s disease patients who are treated with cabergoline while undergoing conventional fractionated radiotherapy have a higher risk of disease recurrence after initial remission, a small study has found. The study, “Cabergoline may act as a radioprotective agent in Cushing’s disease,” was published in Clinical Endocrinology. Radiation…
On average, people with Cushing’s syndrome wait 34 months before receiving a definite diagnosis, but waiting time largely depends on their specific disease subtype, a review study from Germany reports. Cushing’s disease patients — those with a tumor in the pituitary gland — wait the longest for a…
A Phase 3 trial evaluating Corcept Therapeutics‘ relacorilant in treating the high blood pressure and poorer glucose tolerance in people with endogenous Cushing’s syndrome has begun dosing patients in Europe, the company announced. The GRACE trial (NCT03697109) will be conducted at 62 sites in the United States,…
Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.
A European Medicines Agency (EMA) committee has recommended the approval of osilodrostat — to be marketed as Isturisa — for the treatment of adults with Cushing’s syndrome. Osilodrostat, formerly known as LCI699, is an oral treatment that inhibits an enzyme called 11-beta-hydroxylase, which is involved in…
Recent Posts
- Getting vaccinated takes a toll on me as someone with Cushing’s disease
- Protein interaction could point to new Cushing’s treatment approach
- Chronic stress from Cushing’s causes long-term memory loss for me
- FDA gives breakthrough status to continuous cortisol monitoring device
- Embracing the power of hope in life with Cushing’s disease
- FDA grants orphan drug status to experimental Cushing’s therapy
- The buffalo hump is one of my least favorite parts of Cushing’s disease
- Simple blood tests may help doctors monitor Cushing’s disease
- Let’s talk about sex and chronic illness
- Mental health challenges, poor sleep drive night eating in Cushing’s